# Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Gastrointestinal Cancer

> **NCT03474861** · PHASE1 · UNKNOWN · sponsor: **Hangzhou Converd Co., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Gastrointestinal Cancer

## Interventions

- **BIOLOGICAL:** anticancer medication A01; immune cells IC01

## Key facts

- **NCT ID:** NCT03474861
- **Lead sponsor:** Hangzhou Converd Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04
- **Primary completion:** 2019-04
- **Final completion:** 2019-04
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2018-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03474861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03474861, "Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Gastrointestinal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03474861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*